Dinesh K Singh, Rahul K Kollipara, Vamsidara Vemireddy, Xiao-Li Yang, Yuxiao Sun, Nanda Regmi, Stefan Klingler, Kimmo J Hatanpaa, Jack Raisanen, Steve K Cho, Shyam Sirasanagandla, Suraj Nannepaga, Sara Piccirillo, Tomoyuki Mashimo, Shan Wang, Caroline G Humphries, Bruce Mickey, Elizabeth A Maher, Hongwu Zheng, Ryung S Kim, Ralf Kittler, Robert M Bachoo
Efforts to identify and target glioblastoma (GBM) drivers have primarily focused on receptor tyrosine kinases (RTKs). Clinical benefits, however, have been elusive. Here, we identify an SRY-related box 2 (SOX2) transcriptional regulatory network that is independent of upstream RTKs and capable of driving glioma-initiating cells. We identified oligodendrocyte lineage transcription factor 2 (OLIG2) and zinc-finger E-box binding homeobox 1 (ZEB1), which are frequently co-expressed irrespective of driver mutations, as potential SOX2 targets...
January 24, 2017: Cell Reports